Posted by Michael Wonder on 17 Mar 2022
Panel scrutinises quick FDA drug approvals
17 March 2022 - A House committee will spotlight an FDA process that’s been criticised as putting some of the costliest drugs on the market with limited evidence.
The House Energy and Commerce Committee Health Subcommittee will tackle 22 pieces of legislation at a hearing on Thursday about the future of medicine. The hearing comes as the Congress considers legislation to reauthorise user fees, which the FDA takes from drug and device makers to fund its operations.
The current five year authorisation expires 30 September, and the hearing is the first stop for some of these bills to wind up as riders on that must-pass user fee package.
